RNA-targeted therapeutics in cancer clinical trials: Current status and future directions

Pedro Barata; Anil K. Sood; David S. Hong

doi:10.1016/j.ctrv.2016.08.004

RNA-targeted therapeutics in cancer clinical trials: Current status and future directions

Pedro Barata, Anil K. Sood, David S. Hong

Research output: Contribution to journal › Review article › peer-review

125 Scopus citations

Abstract

Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene expression. In this review, we summarize how these approaches were used to develop drugs targeting RNA in human cells. Then, we review the current state of clinical trials of these agents for different types of cancer and outcomes from published data. Finally, we discuss lessons learned from completed studies and future directions for this class of drugs.

Original language	English (US)
Pages (from-to)	35-47
Number of pages	13
Journal	Cancer treatment reviews
Volume	50
DOIs	https://doi.org/10.1016/j.ctrv.2016.08.004
State	Published - Nov 1 2016

Keywords

Antisense oligonucleotides
Cancer clinical trials
RNA therapeutics
miRNA
siRNA

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctrv.2016.08.004

Cite this

@article{fb32c748b7f1473a837cc08e5924ed6a,

title = "RNA-targeted therapeutics in cancer clinical trials: Current status and future directions",

abstract = "Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene expression. In this review, we summarize how these approaches were used to develop drugs targeting RNA in human cells. Then, we review the current state of clinical trials of these agents for different types of cancer and outcomes from published data. Finally, we discuss lessons learned from completed studies and future directions for this class of drugs.",

keywords = "Antisense oligonucleotides, Cancer clinical trials, RNA therapeutics, miRNA, siRNA",

author = "Pedro Barata and Sood, {Anil K.} and Hong, {David S.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.ctrv.2016.08.004",

language = "English (US)",

volume = "50",

pages = "35--47",

journal = "Cancer treatment reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - RNA-targeted therapeutics in cancer clinical trials

T2 - Current status and future directions

AU - Barata, Pedro

AU - Sood, Anil K.

AU - Hong, David S.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene expression. In this review, we summarize how these approaches were used to develop drugs targeting RNA in human cells. Then, we review the current state of clinical trials of these agents for different types of cancer and outcomes from published data. Finally, we discuss lessons learned from completed studies and future directions for this class of drugs.

AB - Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene expression. In this review, we summarize how these approaches were used to develop drugs targeting RNA in human cells. Then, we review the current state of clinical trials of these agents for different types of cancer and outcomes from published data. Finally, we discuss lessons learned from completed studies and future directions for this class of drugs.

KW - Antisense oligonucleotides

KW - Cancer clinical trials

KW - RNA therapeutics

KW - miRNA

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=84986552471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986552471&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2016.08.004

DO - 10.1016/j.ctrv.2016.08.004

M3 - Review article

C2 - 27612280

AN - SCOPUS:84986552471

SN - 0305-7372

VL - 50

SP - 35

EP - 47

JO - Cancer treatment reviews

JF - Cancer treatment reviews

ER -

RNA-targeted therapeutics in cancer clinical trials: Current status and future directions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this